Drugs / Plinabulin
Plinabulin
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02812667 | Aug 2016 → Nov 2024 | non-small cell lung carcinoma | Lyudmila Bazhenova, M.D. | Completed | No outcome recorded |
| Phase 1 | NCT00322608 | Apr 2006 → Sep 2009 | cancer | Nereus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04902040 | Apr 2021 → Feb 2025 | cutaneous melanoma, cutaneous neuroendocrine carcinoma, non-small cell lung carcinoma, renal cell adenocarcinoma +1 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03575793 | Sep 2018 → Sep 2023 | small cell lung carcinoma | Salma Sabbour | Completed | No outcome recorded |
| Phase 1/2 | NCT02846792 | Jun 2017 → Jul 2018 | non-small cell lung carcinoma | University of Washington | Terminated | No outcome recorded |
| Phase 1/2 | NCT00630110 | Feb 2008 → Jun 2011 | cancer | Nereus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05745350 | Mar 2024 → Jun 2025 overdue | small cell lung carcinoma | Xiaorong Dong | Recruiting | No outcome recorded |
| Phase 2 | NCT05599789 | Feb 2023 → Jan 2025 | non-small cell lung carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05130827 | Dec 2021 → Nov 2026 expected | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04227990 | Nov 2017 → Oct 2018 | neutropenia | BeyondSpring Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04345900 | Apr 2017 → Mar 2018 | neutropenia | BeyondSpring Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07361484 | Jun 2026 → Jun 2029 expected | non-small cell lung carcinoma | BeyondSpring Pharmaceuticals Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03294577 | Oct 2019 → Sep 2020 | neutropenia | BeyondSpring Pharmaceuticals Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT03102606 | May → Dec 2018 | neutropenia | BeyondSpring Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02504489 | Dec 2015 → Jul 2021 | non-small cell lung carcinoma | BeyondSpring Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plinabulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05599789 ↗ |
| Known as | BPI-2358 | “The purpose of the study is to determine whether plinabulin (also known as BPI-2358) has an effect on cancer and body in combination with nivolumab, a standard treatment for...” NCT02812667 ↗2“Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity originally developed by Nereus Pharmaceuticals, Inc., and now by BeyondSpring Pharmaceuticals, Inc.” NCT03575793 ↗ “Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds.” NCT04227990 ↗ |
| Known as | NPI-2358 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00630110 ↗ |
| Known as | Plinabulina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1096380 ↗ |
| Known as | Plinabuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL1096380 ↗ |
| Known as | t-butyl-dehydrophenylahistin | “It belongs to the diketopiperazine class of compounds with a chemical name 2, 5-piperazinedione, 3-[[5-(1,1-dimethylethyl)-1H-imidazol-4-yl[methylene]-6-(phenylmethylene)-,...” NCT03575793 ↗ |
| Action | Inhibit | “Plinabulin is a microtubule destabilizing agent (MDA) that inhibits the polymerization of tubulin monomers” NCT02812667 ↗ |
| Modality | Small molecule | “Plinabulin is a novel, non-granulocyte colony-stimulating factor (GCSF) small molecule” PMID 32970104 ↗ Nov 2020 |
| Route | Intravenous | “NPI-2358 Administered Via Intravenous Infusion” NCT00322608 ↗ |